amifostine anhydrous has been researched along with Carcinoma, Papillary in 7 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since differentiated thyroid cancer has a good prognosis, reduction of long-term side effects is important." | 2.69 | Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. ( Bohuslavizki, KH; Brenner, W; Clausen, M; Henze, E; Klutmann, S; Mester, J, 1998) |
| "Xerostomia was graded according to WHO criteria." | 2.69 | Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer. ( Bleckmann, C; Bohuslavizki, KH; Brenner, W; Clausen, M; Henze, E; Klutmann, S; Lassmann, S; Mester, J, 1999) |
| "Xerostomia was graded according to WHO-criteria." | 2.69 | Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer. ( Bleckmann, C; Bohuslavizki, KH; Brenner, W; Buchert, R; Clausen, M; Henze, E; Klutmann, S; Kröger, S; Mester, J, 1999) |
| "Standard treatment of differentiated thyroid cancer includes total thyroidectomy and high-dose Radioactive Iodine Therapy (RIT) for ablation of remnant thyroid tissue." | 1.51 | Radioprotective Effects of Amifostine, L-Carnitine and Vitamin E in Preventing Early Salivary Gland Injury due to Radioactive Iodine Treatment. ( Altun, GD; Ergulen, A; Muratli, A; Serim, BD; Torun, N, 2019) |
| "Because differentiated thyroid cancer has a good prognosis, reduction of long-term side effects is important." | 1.30 | Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. ( Bohuslavizki, KH; Brenner, W; Clausen, M; Feyerabend, B; Henze, E; Hübner, RH; Klutmann, S; Lassmann, S; Lüttges, J; Tinnemeyer, S, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Torun, N | 1 |
| Muratli, A | 1 |
| Serim, BD | 1 |
| Ergulen, A | 1 |
| Altun, GD | 1 |
| Ma, C | 1 |
| Xie, J | 1 |
| Chen, Q | 1 |
| Wang, G | 1 |
| Zuo, S | 1 |
| Mandel, SJ | 1 |
| Mandel, L | 1 |
| Bohuslavizki, KH | 4 |
| Brenner, W | 4 |
| Klutmann, S | 4 |
| Hübner, RH | 1 |
| Lassmann, S | 2 |
| Feyerabend, B | 1 |
| Lüttges, J | 1 |
| Tinnemeyer, S | 1 |
| Clausen, M | 4 |
| Henze, E | 4 |
| Mester, J | 3 |
| Bleckmann, C | 2 |
| Kröger, S | 1 |
| Buchert, R | 1 |
2 reviews available for amifostine anhydrous and Carcinoma, Papillary
| Article | Year |
|---|---|
Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Amifostine; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Radiatio | 2009 |
Radioactive iodine and the salivary glands.
Topics: Amifostine; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Radiation Injuries; Radiation-Protec | 2003 |
3 trials available for amifostine anhydrous and Carcinoma, Papillary
| Article | Year |
|---|---|
Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study.
Topics: Adenocarcinoma, Follicular; Adult; Amifostine; Carcinoma, Papillary; Double-Blind Method; Female; Hu | 1998 |
Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Papillary; Drug Evaluation; Female; Humans; Iodine Radioisotopes | 1999 |
Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Amifostine; Carcinoma, Papillary; Double | 1999 |
2 other studies available for amifostine anhydrous and Carcinoma, Papillary
| Article | Year |
|---|---|
Radioprotective Effects of Amifostine, L-Carnitine and Vitamin E in Preventing Early Salivary Gland Injury due to Radioactive Iodine Treatment.
Topics: Amifostine; Animals; Carcinoma, Papillary; Carnitine; Guinea Pigs; Injections, Intramuscular; Iodine | 2019 |
Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Amifostine; Animals; Carcinoma, Papillary; Case-Control Stu | 1998 |